Naxitamab has actually been authorized for pediatric and adult patients with relapsed/refractory neuroblastoma in the bone and bone marrow that has reacted to prior therapy. FDA Approvals
Find Out More
Naxitamab has actually been authorized for pediatric and adult patients with relapsed/refractory neuroblastoma in the bone and bone marrow that has reacted to prior therapy. FDA Approvals
Find Out More